Immunovant, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Immunovant, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($413.84M) | May 29, 2025 |
| FY2025 | Mar 31, 2024 | ($259.34M) | May 29, 2025 |
| FY2025 | Mar 31, 2023 | ($210.96M) | May 29, 2025 |
| FY2023 | Mar 31, 2022 | ($156.73M) | May 22, 2023 |
| FY2022 | Mar 31, 2021 | ($107.43M) | Jun 8, 2022 |
| FY2020 | Mar 31, 2020 | ($66.39M) | Jun 1, 2021 |
| FY2019 | Mar 31, 2019 | ($24.23M) | Jun 29, 2020 |
| FY2019 | Jul 6, 2018 | ($4.37M) | Jun 29, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Mar 31, 2022 | $101.81M | Jun 8, 2022 |
| FY2022 | Mar 31, 2021 | $68.60M | Jun 8, 2022 |
| FY2020 | Mar 31, 2020 | $47.93M | Jun 1, 2021 |
| FY2019 | Mar 31, 2019 | $25.73M | Jun 29, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($375.87M) | May 29, 2025 |
| FY2025 | Mar 31, 2024 | ($214.23M) | May 29, 2025 |
| FY2025 | Mar 31, 2023 | ($188.19M) | May 29, 2025 |
| FY2023 | Mar 31, 2022 | ($106.11M) | May 22, 2023 |
| FY2022 | Mar 31, 2021 | ($83.33M) | Jun 8, 2022 |
| FY2020 | Mar 31, 2020 | ($53.36M) | Jun 1, 2021 |
| FY2019 | Mar 31, 2019 | ($28.55M) | Jun 29, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $759.0K | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $360.0K | May 29, 2025 |
| FY2025 | Mar 31, 2023 | $197.0K | May 29, 2025 |
| FY2023 | Mar 31, 2022 | $254.0K | May 22, 2023 |
| FY2022 | Mar 31, 2021 | $210.0K | Jun 8, 2022 |
| FY2020 | Mar 31, 2020 | $31.0K | Jun 1, 2021 |
| FY2019 | Mar 31, 2019 | $52.0K | Jun 29, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $776.22M | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $666.37M | May 29, 2025 |
| FY2024 | Mar 31, 2023 | $405.84M | May 29, 2024 |
| FY2023 | Mar 31, 2022 | $515.56M | May 22, 2023 |
| FY2022 | Mar 31, 2021 | $412.49M | Jun 8, 2022 |
| FY2020 | Mar 31, 2020 | $109.39M | Jun 1, 2021 |
| FY2019 | Mar 31, 2019 | $13.83M | Jun 29, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $68.78M | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $48.61M | May 29, 2025 |
| FY2024 | Mar 31, 2023 | $43.34M | May 29, 2024 |
| FY2023 | Mar 31, 2022 | $45.74M | May 22, 2023 |
| FY2022 | Mar 31, 2021 | $21.01M | Jun 8, 2022 |
| FY2020 | Mar 31, 2020 | $15.32M | Jun 1, 2021 |
| FY2019 | Mar 31, 2019 | $6.49M | Jun 29, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $707.45M | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $617.76M | May 29, 2025 |
| FY2025 | Mar 31, 2023 | $362.49M | May 29, 2025 |
| FY2025 | Mar 31, 2022 | $469.83M | May 29, 2025 |
| FY2023 | Mar 31, 2021 | $391.48M | May 22, 2023 |
| FY2022 | Mar 31, 2020 | $94.07M | Jun 8, 2022 |
| FY2020 | Mar 31, 2019 | $7.34M | Jun 1, 2021 |
| FY2019 | Jul 6, 2018 | ($411.0K) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($1.50M) | Jun 29, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.24B) | May 29, 2025 |
| FY2025 | Mar 31, 2024 | ($825.68M) | May 29, 2025 |
| FY2024 | Mar 31, 2023 | ($566.35M) | May 29, 2024 |
| FY2023 | Mar 31, 2022 | ($355.39M) | May 22, 2023 |
| FY2022 | Mar 31, 2021 | ($198.66M) | Jun 8, 2022 |
| FY2020 | Mar 31, 2020 | ($91.23M) | Jun 1, 2021 |
| FY2019 | Mar 31, 2019 | ($24.84M) | Jun 29, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $713.97M | May 29, 2025 |
| FY2025 | Mar 31, 2024 | $635.37M | May 29, 2025 |
| FY2024 | Mar 31, 2023 | $376.53M | May 29, 2024 |
| FY2023 | Mar 31, 2022 | $493.82M | May 22, 2023 |
| FY2022 | Mar 31, 2021 | $400.15M | Jun 8, 2022 |
| FY2020 | Mar 31, 2020 | $100.57M | Jun 1, 2021 |
| FY2019 | Mar 31, 2019 | $6.99M | Jun 29, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (2) | May 29, 2025 |
| FY2025 | Mar 31, 2024 | (1) | May 29, 2025 |
| FY2025 | Mar 31, 2023 | (1) | May 29, 2025 |
| FY2023 | Mar 31, 2022 | (1) | May 22, 2023 |
| FY2022 | Mar 31, 2021 | (1) | Jun 8, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (2) | May 29, 2025 |
| FY2025 | Mar 31, 2024 | (1) | May 29, 2025 |
| FY2025 | Mar 31, 2023 | (1) | May 29, 2025 |
| FY2023 | Mar 31, 2022 | (1) | May 22, 2023 |
| FY2022 | Mar 31, 2021 | (1) | Jun 8, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 170.11M | May 29, 2025 |
| FY2025 | Mar 31, 2024 | 145.58M | May 29, 2025 |
| FY2024 | Mar 31, 2023 | 130.33M | May 29, 2024 |
| FY2023 | Mar 31, 2022 | 116.48M | May 22, 2023 |
| FY2022 | Mar 31, 2021 | 97.97M | Jun 8, 2022 |
| FY2020 | Mar 31, 2020 | 54.66M | Jun 1, 2021 |
| FY2019 | Mar 31, 2019 | 38.59M | Jun 29, 2020 |